7 results about "CC chemokine" patented technology

An immune response may be induced in a subject by administering to the subject a first mRNA construct encoding a homeostatic chemokine, a cytokine, or a fragment thereof, and a second antigen mRNA construct encoding an antigen. The first mRNA construct may encode a homeostatic chemokine, which is a monomeric peptide with a disulfide bridge formed by bonding between two cysteine moieties in the homeostatic chemokine. The homeostatic chemokine may be selected from the group consisting of a CXC chemokine, a CC chemokine, a CX3C chemokine, and a C chemokine. The first mRNA construct may be used as a genetic adjuvant which potentiates an immune response to a target antigen.

A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4− IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab aim exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of a cancer.

This invention relates to N-substituted dioxocyclobutenylamino-3-hydroxypyridine carboxamide compounds of formulas (IIA) and (IIB) that inhibit CC chemokine receptor 6 (CCR6), or pharmaceutically acceptable salts thereof; pharmaceutical compositions containing these compounds; and the use of these compounds for the treatment or prevention of diseases, conditions, or ailments that are improved by inhibiting CCR6.